Lymphomatoid Papulosis in a Patient Treated with Adalimumab for Juvenile Rheumatoid Arthritis
Lymphomatoid Papulosis in a Patient Treated with Adalimumab for Juvenile Rheumatoid Arthritis
复制标题
DOI：
10.1159/000345104
复制
发表时间：
2012-01-01
期刊：
影响因子：
3.4
通讯作者：
Koh, Eun-Mi
中科院分区：
文献类型：
--
作者：
Park, Ji-Hye;Lee, Jun;Koh, Eun-Mi
抗肿瘤坏死因子药物现在被认为是多种免疫调节疾病的高效治疗手段，包括类风湿性关节炎、克罗恩病和牛皮癣。这类药物的作用机制包括阻断源自肿瘤坏死因子-α的多个细胞内信号通路，最终导致全身免疫抑制状态。事实上，在接受抗肿瘤坏死因子-α药物治疗的患者中已经报告了几例淋巴瘤病例，尽管很难证明任何程度的因果关系。在这里，我们描述了一名患者，他在接受阿达利马治疗后发展为淋巴瘤样丘疹，由此可以建立明确的因果关系。版权所有(C)2012 S.Karger AG，巴塞尔
Anti-tumor necrosis factor (TNF) agents are now well regarded as highly effective treatment modalities for multiple immunologically mediated diseases, including rheumatoid arthritis, Crohn's disease and psoriasis. The mechanism of action for this particular class of medications involves the blockade of multiple intracellular signaling pathways originating from TNF-alpha, ultimately inducing a generalized immunosuppressed state. In fact, several cases of lymphomas have been reported in patients treated with anti-TNF-alpha agents, though it has been difficult to prove any degree of causality. Herein, we described a patient who developed lymphomatoid papulosis after being treated with adalimumab, whereby a clear causality could be established. Copyright (C) 2012 S. Karger AG, Basel